David Silberman - Jan 3, 2022 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)

Role
Chief Financial Officer
Signature
/s/ David Silberman
Stock symbol
ORMP
Transactions as of
Jan 3, 2022
Transactions value $
$0
Form type
4
Date filed
1/5/2022, 07:32 PM
Previous filing
Sep 2, 2021
Next filing
Aug 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORMP Common Stock Award +19K +38% 69K Jan 3, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORMP Stock Option (right to buy) Award $0 +32K $0.00 32K Jan 3, 2022 Common Stock 32K $13.89 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 4,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.
F2 The Stock Option will vest in 4 installments as follows: 8,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.